Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Beneficient Cl A (BENF)

Beneficient Cl A (BENF)
0.3112 x 10 0.3249 x 7
Post-market by (Cboe BZX)
0.3249 +0.0029 (+0.90%) 03/13/25 [NASDAQ]
0.3112 x 10 0.3249 x 7
Post-market 0.2975 -0.0274 (-8.43%) 17:41 ET
News & Headlines for Thu, Mar 13th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Beneficient Announces Agreement to Settle GWG Litigation

BENF : 0.3249 (+0.90%)
Beneficient Reports Results for Third Quarter Fiscal 2025

BENF : 0.3249 (+0.90%)
Beneficient Announces Third Quarter Fiscal 2025 Earnings Release and Webcast

BENF : 0.3249 (+0.90%)
Beneficient Enters into $1.36 Million GP Primary Capital Transaction

BENF : 0.3249 (+0.90%)
Beneficient Enters into Transactions to Deliver Tangible Book Value and Other Benefits to Beneficient Public Company Stockholders Provided by Entities Controlled by CEO & Founder, Brad Heppner, and Other Founders

BENF : 0.3249 (+0.90%)
Beneficient Hires Industry Veteran Louise Jones to Lead Capital Markets and Custody Business Line Operations

BENF : 0.3249 (+0.90%)
Beneficient Announces Agreement to Acquire Mercantile Bank International Corp. for $1.5 Million in Stock and Cash

Beneficient plans to acquire Mercantile Bank for $1.5 million, enhancing alternative asset custody services and revenue opportunities.Quiver AI SummaryBeneficient, a technology-based platform focused on...

BENF : 0.3249 (+0.90%)
Beneficient Enters into Agreement to Acquire Mercantile Bank International to Expand its Alternative Asset Custody Services

BENF : 0.3249 (+0.90%)
Beneficient to Present at Emerging Growth Conference on December 4, 2024

Beneficient will present at the Emerging Growth Conference on December 4, 2024, showcasing its alternative asset solutions.Quiver AI SummaryBeneficient (NASDAQ: BENF), a technology platform that provides...

BENF : 0.3249 (+0.90%)
Beneficient to Present at the Emerging Growth Conference on December 4, 2024

BENF : 0.3249 (+0.90%)

Barchart Exclusives

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?
Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals